

KEY INFORMATION DOCUMENT

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

LO Selection - NextGen BioTech, Syst. Hdg, (EUR), MA

Name of the PRIIP manufacturer: Lombard Odier Funds (Europe) S.A. part of Lombard Odier Group.

ISIN: LU2265260138

Website of the PRIIP manufacturer: www.loim.com

Call +41 22 709 9333 or write to loim-client-servicing@lombardodier.com for more information.

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising Lombard Odier Funds (Europe) S.A. in relation to this Key Information Document. Lombard Odier Funds (Europe) S.A. is authorised in Luxembourg and regulated by the CSSF.

Lombard Odier Funds (Europe) S.A. acts as management company under Chapter 15 of the Luxembourg law of 17 December 2010 on undertakings for collective investment.

This PRIIP is authorized in Luxembourg.

Date of revision and production: 01 January, 2023.

What is this product ?

Type

The Sub-Fund is part of the Fund LO Selection, a public liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg as an investment company with variable share capital. The Fund is subject to part I of the Luxembourg law of 17 December 2010 relating to undertakings for collective investment in transferable securities ("UCITS").

Term

The Sub-Fund has no maturity date. The PRIIP manufacturer is entitled to terminate the Sub-Fund unilaterally under the circumstances provided for in the constitutive documents of the Fund. A liquidation of the Fund will cause the automatic termination of the Sub-Fund.

Objectives

The Sub-fund is actively managed in reference to a benchmark. The NASDAQ Biotechnology Net TR Index (the "Benchmark") is used for performance comparison and for internal risk monitoring purposes only, without implying any particular constraints to the Sub-Fund's investments. The Sub-Fund's securities will generally be members of the Benchmark but the security weightings are expected to differ materially. The Investment Manager will select securities not included in the Benchmark in order to take advantage of investment opportunities. The Sub-Fund invests primarily in equity securities or equity-related securities issued by companies worldwide (including Emerging Markets) exercising a prominent part of their business activities in the healthcare industry. The Investment Manager's approach focuses on small and mid-cap biotechnology companies providing positive impact through disruptive, next generation innovations that can bring, among other things, better treatment solutions while lowering the financial burden for society. The Investment Manager will use its discretion with regard to the selection of markets, size of companies and currencies. The Sub-Fund may (i) hold on a temporary and ancillary basis up to 30% of its net assets in Cash and Cash Equivalents and (ii) hold up to 10% of its net assets in UCIs. Subject to the limits permitted by the Investment Restrictions described in Section 4 of the Prospectus, the Investment Manager is authorized to use financial derivative instruments for hedging and efficient portfolio management purposes, but not as part of the investment strategy. As part of its Emerging Market exposure, the Sub-Fund may invest up to 20% of its net assets in shares issued by mainland China-incorporated companies (including China A-Shares).

The Sub-Fund may exhibit very high volatility due to its exposure to Small and Mid capitalisation companies in developed equity markets that have been subject in the past to elevated price fluctuations.

This Sub-Fund may not be appropriate for investors who plan to withdraw their money within 5 years.

Sustainability

The Fund has been classified as a financial product subject to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (the "SFDR"). The Fund promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices.

Benchmark

A proxy benchmark has been identified for performance comparison: NASDAQ Biotechnology Index USD ND (EUR Cross Hdg.).

Additional information

You can find information about the SICAV, its sub-funds and the available share classes online at www.loim.com. This includes information on how to buy or sell shares or switch between the SICAV's various sub-funds. The Prospectus, annual and semi-annual reports for the SICAV and the details of the up-to-date remuneration policy of Lombard Odier Funds (Europe) S.A. can be obtained free of charge from the website www.loim.com and from the SICAV's registered office, at 291, route d'Arlon, L-1150 Luxembourg.

The net asset value per share is calculated daily and is available at www.loim.com and at the registered office of the SICAV.

Distribution policy: Income Accumulated.

Dealing frequency: You may redeem shares in this Sub-Fund on demand on a daily basis.


The depositary is CACEIS Bank, Luxembourg Branch.


Intended retail investor

The Sub-Fund is intended for eligible investors who have sufficient experience or have obtained professional advice to assess the risk of investing, have a long-term investment horizon and have sufficient resources to be able to bear any losses (which may equal to the total amount invested) that may result from an investment in the Sub-Fund.

What are the risks and what could I get in return ?

RISK AND REWARD PROFILE



 The risk indicator assumes you keep the product for 5 years. Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact our capacity to pay you.

The following risks may be materially relevant but may not always be adequately captured by the synthetic risk indicator and may cause additional loss: Concentration risk, Active management risk and Financial, economic, regulatory and political risks.

PERFORMANCE SCENARIOS

The figures shown include all the costs of the product itself. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. Markets could develop very differently in the future. The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of a suitable benchmark over the last 10 years. These types of scenario occurred for an investment between 31.10.2012 and 31.10.2022. The stress scenario shows what you might get back in extreme market circumstances.

Recommended holding period: 5 years
Example Investment EUR 10 000

Scenarios		If you cash in after 1 year	If you cash in after 5 years (recommended)
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress scenario	What you might get back after costs	EUR 2 640	EUR 0
	Average return each year	-73.60%	-100.00%
Unfavourable scenario	What you might get back after costs	EUR 4 960	EUR 0
	Average return each year	-50.38%	-100.00%
Moderate scenario	What you might get back after costs	EUR 10 950	EUR 12 280
	Average return each year	9.47%	4.20%
Favourable scenario	What you might get back after costs	EUR 17 820	EUR 24 100
	Average return each year	78.24%	19.23%

What happens if Lombard Odier Funds (Europe) S.A. is unable to pay out?

You may face a financial loss should the manufacturer or depositary, default on their obligations.

There is no compensation or guarantee scheme in place which may offset, all or any of, these potential losses.

What are the costs ?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- the product performs as shown in the moderate scenario
- EUR 10 000 is invested

Example Investment EUR 10 000	If you cash in after 1 year	If you cash in after 5 years (recommended)
Total costs	EUR 186	EUR 998
Annual cost impact*	1.86%	1.64%

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 5.84% before costs and 4.20% after costs. We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

The table below shows the impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period and what the different cost categories mean.

COMPOSITION OF COSTS

One-off costs upon entry or exit		If you exit after 1 year	If you exit after 5 years
Entry costs	This is the amount you pay in when entering this investment.	EUR 0	EUR 0
Exit costs	This is the amount of your investment that is taken before it is paid out to you.	EUR 0	EUR 0
Ongoing costs taken each year			
Management fees and other administrative or operating costs	This is the amount you will pay based on an estimate of all the management and operational costs (besides transaction cost).	EUR 158	EUR 848
Transaction costs	This is the amount you will pay based on an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell. Additional fees linked to investment into underlying funds may also be charged.	EUR 28	EUR 150
Incidental costs			
Performance fees	The actual amount charged will vary depending on how well your investment performs.	EUR 0	EUR 0

How long should I hold it and can I take money out early ?

Minimum recommended holding period: 5 years

This product has no required minimum holding period but is designed for long term investment.

How can I complain ?

If you have any complaints about the product or conduct of the manufacturer or the person advising on, or selling the product, you may lodge your complaint in one of three ways:

- You can contact our complaints hotline on +352 27 78 1000 who will log your complaint and explain what to do.
- You may log your complaint via email at luxembourg-funds@lombardodier.com
- You may send your complaint in writing to Complaints Department, Lombard Odier Funds (Europe) S.A. 291, route d'Arlon L 1150 Luxembourg

Other relevant information

Other policy documentation pertaining to the product, the latest prospectus, annual and semi-annual reports, updated PRIIP KID and other product information is available online at www.loim.com. Past performance historical data can be found for the latest 1 years at www.loim.com.

Specific information for Swiss investors: Representative in Switzerland: Lombard Odier Asset Management (Switzerland) SA; 6, avenue des Morgines; 1213 Petit-Lancy, the Swiss Paying Agent: Bank Lombard Odier & Co Ltd; 11, rue de la Corraterie; 1204 Genève. The above documents can be obtained free of charge from the representative in Switzerland.